Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Recruiting 2Not yet recruiting 2Active not recruiting 2Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasm Metastasis 10Carcinoma, Non-Small-Cell Lung 10Breast Neoplasms 9Lung Neoplasms 5Prostatic Neoplasms 4Pancreatic Neoplasms 4Neoplasms 4Leukemia, Myeloid, Acute 4Colorectal Neoplasms 4Triple Negative Breast Neoplasms 3Rectal Neoplasms 3Melanoma 3Leukemia 3Glioblastoma 3Cholangiocarcinoma 3Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Recurrence 2Gliosarcoma 2Glioma 2Congenital Abnormalities 2Colonic Neoplasms 2Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Thrombocythemia, Essential 1Stomatitis 1Primary Myelofibrosis 1Polycythemia Vera 1Pleural Effusion, Malignant 1Pain 1

Interventions

Gemcitabine 25Cisplatin 19pembrolizumab 11avelumab 10Nivolumab 7Mitomycin 6Carboplatin 6apaziquone 5Paclitaxel 5Vinblastine 4Methotrexate 4Doxorubicin 4Docetaxel 4BCG Vaccine 4vofatamab 3durvalumab 3atezolizumab 3Sunitinib 3Standard of Care 3Sorafenib 3Radiotherapy, Intensity-Modulated 3Radiotherapy 3Radiation 3Magnetic Resonance Spectroscopy 3Lapatinib 3Cystectomy 3B701 protein, Human herpesvirus 6 3valrubicin 2rucaparib 2enfortumab vedotin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Urinary Bladder Neoplasms × Drug Therapy × Clear all
NCT01094496 2020-02-13

A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The "N-ABLE" Study)

Celldex Therapeutics

Phase 2 Terminated
3 enrolled
Genitourinary

Urinary Bladder Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡